A Poly(lactic Acid)‐Porphyrin‐Cobalt Vaccine Adjuvant System Elicits Protein‐ or Peptide‐Specific Humoral and Cellular Immunity
Advanced Materials · 2026
DOI: 10.1002/adma.74905 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Lisen Lu und 10 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, Hainan Medical University, Haikou, Hainan, China. Hauptthemen laut MEDLINE: Immunity, Cellular, Immunity, Humoral, Polyesters, Adjuvants, Immunologic. Die Arbeit nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Youth Fund of the Natural Science Foundation of Hubei Province, Special Fund for Technological Innovation of Hubei.
Abstract (Originalsprache)
There is growing interest in vaccine adjuvant systems that are scalable, adaptable, and capable of stimulating humoral and cellular immune responses with recombinant protein or synthetic peptide immunogens. In this study, we introduced a “plug‐and‐play” nanoadjuvant system consisting of poly(lactic acid)‐porphyrin‐cobalt ion co‐formulated with immunostimulatory saponin QS‐21 (PPCoQ). PPCoQ facilitated subunit vaccine assembly by coordinating antigens' polyhistidine tags with immobilized cobalt (Co 2+ ) within a porphyrin‐modified poly(lactic acid). Using the receptor‐binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) as a model antigen, the resulting nanovaccine, PPCoQ‐RBD, induced high levels of anti‐RBD antibodies in transgenic mice expressing human ACE2. Following viral challenge, immunized mice achieved a 99.7% clearance rate of the SARS‐CoV‐2 Omicron variant, demonstrating strong humoral and cellular immune responses. Additionally, PPCoQ‐RBD was compatible with nebulization‐based inhalation, which enhanced mucosal immunity, increased IgA antibody titers, and promoted the formation of abundant tissue‐resident memory T cells. A model T cell epitope (OVA) was formulated to evaluate cellular responses, generating PPCoQ‐OVA, which significantly inhibited B16‐OVA tumor growth. The PPCoQ vaccine adjuvant system is easy to produce and supports efficient antigen loading, lymph node targeting, lysosomal escape, and biocompatibility, and has broad prospects for application and clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, Hainan Medical University, Haikou, Hainan, China.
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, P. R. China.
- College of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, P. R. China.
- Department of Biomedical Engineering, University At Buffalo, State University of New York, Buffalo, New York, USA.
ORCID-Profile: Lisen Lu, Deqiang Deng, Yuanyuan Geng, Jonathan F Lovell, Muyang Yang, Honglin Jin
Förderung
- National Natural Science Foundation of China
- Youth Fund of the Natural Science Foundation of Hubei Province
- Special Fund for Technological Innovation of Hubei
Zitieren
APA
Lu, L., Deng, D., Sun, J., Geng, Y., Wang, R., Deng, Z., Liu, L., Shi, X., Lovell, J. F., Yang, M., & Jin, H. (2026). A Poly(lactic Acid)‐Porphyrin‐Cobalt Vaccine Adjuvant System Elicits Protein‐ or Peptide‐Specific Humoral and Cellular Immunity. Advanced Materials. https://doi.org/10.1002/adma.74905
Vancouver
Lu L, Deng D, Sun J, Geng Y, Wang R, Deng Z, et al. A Poly(lactic Acid)‐Porphyrin‐Cobalt Vaccine Adjuvant System Elicits Protein‐ or Peptide‐Specific Humoral and Cellular Immunity. Advanced Materials. 2026. doi:10.1002/adma.74905
BibTeX
@article{Lu2026,
author = {Lu, Lisen and Deng, Deqiang and Sun, Jinfeng and Geng, Yuanyuan and Wang, Ruohan and Deng, Zihan and Liu, Li and Shi, Xiujuan and Lovell, Jonathan F and Yang, Muyang and Jin, Honglin},
title = {A Poly(lactic Acid)‐Porphyrin‐Cobalt Vaccine Adjuvant System Elicits Protein‐ or Peptide‐Specific Humoral and Cellular Immunity},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.74905}
}
EUVIMED